Bicara Current Ratio from 2010 to 2025
| BCAX Stock | 17.27 0.28 1.60% |
Current Ratio | First Reported 2010-12-31 | Previous Quarter 27.9340189 | Current Value 29.33 | Quarterly Volatility 10.07123788 |
Check Bicara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bicara Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 196.3 K, Net Interest Income of 15.3 M or Interest Income of 15.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.02. Bicara financial statements analysis is a perfect complement when working with Bicara Therapeutics Valuation or Volatility modules.
Check out the analysis of Bicara Therapeutics Correlation against competitors. Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.